Is GRI Bio Inc (GRI) Stock a Good Investment?
Learn more about GRI Bio Inc's (GRI) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Commentary & Analysis
Financial Summary
| Share Statistics | GRI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.1 | $227.3 | 3% |
|
| Shares Out (Mil) | 1.8 | 53.4 | 7% |
|
| Institutional Ownership | 100.0% | 92.9% | 99% |
|
| Float (Mil) | 2.2 | 41.4 | 6% |
|
| Beta | -0.66 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 39 | 468 | 27% |
|
| Price Change (52-week) |
(96.8%) | 47.4% | 3% |
|
| Growth | GRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (36.9%) | (10.1%) | 11% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.840) | ($3.895) | ($2.000) | |
| Month Ago EPS | ($0.840) | ($3.895) | ($2.000) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.080) | ($4.770) | ($2.535) | |
| Year/Year Chg | (7.7%) | (96.8%) | (99.9%) | |
| Financials | GRI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($44) | 29% |
|
| EPS (TTM) | ($11.554) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($34) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($8) | $174 | 2% |
|
| Valuation | GRI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.30 | 2.14 | 6% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | GRI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (113.3%) | (47.1%) | 5% |
|
| ROE | (142.0%) | (52.0%) | 6% |
|
| Liabilities to Assets | 9.7% | 29.7% | 6% |
|
| F-Score | 2 | 2 | na |
|
GRI Bio, Inc. did not pass any screens on 11/4/2026.
